SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Busque Philippe

(Last)

(First)

(Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BLVD.

(Street)

FREMONT

94538

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/28/2023

3. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Global Sales and Services

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	⁽¹⁾	⁽¹⁾	Common Stock	24,590	⁽²⁾	D
Restricted Stock Units	⁽³⁾	⁽³⁾	Common Stock	5,464	⁽²⁾	D
Employee Stock Option (right to buy)	⁽⁴⁾	03/20/2033	Common Stock	37,562	$9.15	D

Explanation of Responses:

1. The shares subject to the Restricted Stock Units (the "RSU Award") shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter.

2. Each RSU Award represents a contingent right to receive one share of the Issuer's common stock.

3. The shares subject to the RSU Award shall vest on March 20, 2024.

4. The shares subject to the option vest as follows: 25% of the shares subject to the option vests on March 20, 2024; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.

Remarks:

	/s/ Valerie Barnett, Attorney-in-Fact for Philippe Busque	08/29/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.